It’s Clear How Big Money Flows Lift Supernus

SUPN develops and sells treatments for central nervous system diseases, including Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC. In its second-quarter fiscal 2025 earnings report, SUPN showed $165 million in revenue, launched a new treatment for Parkinson’s disease, and drove growth across several key products. Also, it’s poised to gain with interest rate cuts.

It’s no wonder SUPN shares are up 46% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Supernus Gets Big Money Buys

Institutional volumes reveal plenty. In the last year, SUPN has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in SUPN shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Supernus.

Supernus Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, SUPN has had strong sales and earnings growth:

• 1-year sales growth rate (+8.9%)
• 3-year EPS growth rate (+1,792.4%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +36.2%.

Now it makes sense why the stock has been generating Big Money interest. SUPN has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Supernus has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s drawn 36 outlier inflow signals since 2015 and is up 352% since Big Money bought big in March 2015. The blue bars below show when SUPN was a top pick on the Outlier 20 report in the last year…it’s becoming a Big Money favorite:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Supernus Price Prediction

The SUPN action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author owns SUPN in personal and managed accounts at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.